EMA Authorised: Vyndaqel (tafamidis) — Pfizer Europe MA EEIG

View source ↗

Summary

Authorised status for Vyndaqel (tafamidis) from EMA, with orphan designation, for amyloidosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyloidosis

Drugs mentioned

• Vyndaqel (tafamidis)

Snippet

Status: Authorised. Therapeutic area: Amyloidosis. MAH: Pfizer Europe MA EEIG. Decision date: 12/03/2026. Orphan medicine